Evidence map›Paper›PMID 38253081›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2023

[Progress in the clinical cure of the population of inactive hepatitis B surface antigen carriers].

Z S Mo, Z L Gao

Open access · greenAbstract readReviewEnglish Abstract
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Z S MoDepartment of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Z L GaoDepartment of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Third Affiliated Hospital of Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The population of inactive HBsAg carriers (IHCs) is enormous, and it is often overlooked because of the insidious progression and mild severity of the disease. With the continuous enrichment and consolidation of research evidence, the population of IHC has obtained a high clinical cure rate through a treatment strategy based on pegylated interferon α and a stronger treatment intention. This article reviews the definition and treatment recommendations of IHCs in current domestic and international guidelines, as well as the disease progression and clinical cure research progress, so as to provide a reference and basis for scientific management and rational therapeutics.

Indexed as

Hepatitis B Surface AntigensInterferon-alphaHepatitis B Surface AntigensInterferon-alphaClinical cureDisease progressionHBsAg clearanceHepatitis B surface antigenInactive hepatitis B surface antigen carriersPegylated interferon alpha

Identifiers

PMID38253081
PMCPMC12814138
OpenAlexW4391144701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.